Second-line international multicenter study of GlaxoSmithKline’s lapatinib in combination with once-weekly paclitaxel versus once-weekly paclitaxel alone in ErbB-2-positive advanced gastric cancerLapatinib is a new anti-cancer drug developed by GlaxoSmithKline and is currently being tried in some gastric cancer patients in Japan and abroad.Lapatinib is a drug that inhibits cancer proliferation by Lapatinib is a drug that inhibits cancer proliferation by blocking ErbB1 and ErbB2 cancer proliferation signals. In vitro and animal tests have confirmed that lapatinib has a significant inhibitory effect on ErbB1 and ErbB2-expanding cancer cells and is therefore expected to be an effective drug for cancer treatment. Patients with gastric cancer who meet the following major criteria may meet the enrollment criteria 1. all histologically or cytologically confirmed gastric cancer, age ≥ 20 years; patients with ErbB2 amplification detected by FISH in primary or metastatic tumor tissue; 2. patients who have received chemotherapy including 5-fluorouracil and/or cisplatin regimens and are now determined to have progressive gastric cancer; 3. measurable lesions according to RECIST criteria; 4. normal cardiac function, with left ventricular ejection fraction within 5. Appropriate organ function; if you meet the enrollment criteria, treatment drugs are provided free of charge, and the associated examination costs will be free of charge.